Skip to main content
Signal8
Launch Terminal

NewAmsterdam Pharma Co N.V. (NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMSHealthcare
-3.37%$20.06
AH$20.00-0.30%vs close
Mkt Cap$2.4B
Float86.23M
O/S119.54M
Vol
$ Vol
RVOL
Inst Own101.9%
SI16.4%
Earnings
Dilution
NewAmsterdam Pharma Company N.V. logoNASDAQ:NAMS$20.06-3.37%
Phase Distribution
20 lead-sponsored trials·6 active·13 completed
Phase 16
Phase 28
Phase 36
(1 more as collaborator)
Status Overview
Recruiting3
Active, not recruiting3
Completed13
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

    Placebo, Obicetrapib

    Dyslipidemias, High Cholesterol +3

    Enrollment
    2,530
    Start
    Dec 2021
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT05142722
  • Phase 3
    Active, not recruiting

    Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

    Obicetrapib, Placebo

    Atherosclerotic Cardiovascular Disease

    Enrollment
    9,541
    Start
    Feb 2022
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2026est.
    NCT05202509
  • Phase 3
    Completed

    Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

    Obicetrapib, Placebo

    Dyslipidemias, High Cholesterol +7

    Enrollment
    354
    Start
    Jul 2022
    Primary Completion
    May 2024
    Completion
    May 2024
    NCT05425745
  • Phase 3
    Completed

    Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

    Monotherapy obicetrapib, Monotherapy ezetimibe

    Dyslipidemias, Hypercholesterolemia +3

    Enrollment
    407
    Start
    Mar 2024
    Primary Completion
    Sep 2024
    Completion
    Oct 2024
    NCT06005597
  • Phase 3
    Active, not recruiting

    A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

    obicetrapib 10 mg + ezetimibe 10 mg FDC daily

    Lipidemia, Coronary Artery Disease +1

    Enrollment
    300
    Start
    May 2024
    Primary Completion
    Nov 2027est.
    Completion
    Feb 2028est.
    NCT06305559
  • Phase 3
    Active, not recruiting

    A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

    obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg

    Lipidemia, Type 2 Diabetes (T2DM) +1

    Enrollment
    300
    Start
    Dec 2025
    Primary Completion
    Mar 2028est.
    Completion
    Jun 2028est.
    NCT07219602
  • Phase 2
    Completed

    Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

    Obicetrapib

    Dyslipidemias, High Cholesterol +1

    Enrollment
    120
    Start
    Feb 2021
    Primary Completion
    May 2021
    Completion
    Aug 2021
    NCT04753606
  • Phase 2
    Completed

    Randomized Study of Obicetrapib in Combination With Ezetimibe

    Obicetrapib 5mg, Ezetimibe 10mg

    Dyslipidemias, High Cholesterol +1

    Enrollment
    112
    Start
    Feb 2021
    Primary Completion
    May 2021
    Completion
    Jun 2021
    NCT04770389
  • Phase 2
    Completed

    Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

    Obicetrapib

    Early Alzheimer's Disease

    Enrollment
    13
    Start
    Jan 2022
    Primary Completion
    May 2023
    Completion
    Jun 2023
    NCT05161715
  • Phase 2
    Completed

    Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

    Obicetrapib, Ezetimibe 10mg

    Dyslipidemias, High Cholesterol +1

    Enrollment
    119
    Start
    Mar 2022
    Primary Completion
    Aug 2022
    Completion
    Sep 2022
    NCT05266586
  • Phase 2
    Completed

    A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

    Obicetrapib, Placebo

    Dyslipidemia, Hypercholesterolemia +1

    Enrollment
    102
    Start
    Jun 2022
    Primary Completion
    Mar 2023
    Completion
    Apr 2023
    NCT05421078
  • Phase 2
    Recruiting

    Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

    obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

    Dyslipidemias

    Enrollment
    69
    Start
    Dec 2024
    Primary Completion
    Nov 2026est.
    Completion
    Feb 2027est.
    NCT06496243
  • Phase 2
    Recruiting

    Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

    Obicetrapib 10mg, Placebo

    Antioxidant Absorption

    Enrollment
    100
    Start
    Sep 2025
    Primary Completion
    Sep 2026est.
    Completion
    Dec 2026est.
    NCT06982508
  • Phase 2
    Recruiting

    Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

    Obicetrapib 10 mg, Matching placebo tablets

    Preclinical Alzheimer's Disease

    Enrollment
    400
    Start
    Sep 2026est.
    Primary Completion
    Sep 2028est.
    Completion
    May 2029est.
    NCT07794670
  • Phase 1
    Unknown status

    Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

    Obicetrapib

    Lipid Metabolism

    Enrollment
    22
    Start
    Dec 2023
    Primary Completion
    Sep 2024est.
    Completion
    Oct 2024est.
    NCT05972278
  • Phase 1
    Completed

    PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

    Obicetrapib

    Hepatic Impairment, Healthy

    Enrollment
    18
    Start
    Nov 2023
    Primary Completion
    Mar 2024
    Completion
    Mar 2024
    NCT06048302
  • Phase 1
    Completed

    Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

    Fixed-Dose Combination (FDC) Tablet

    Healthy Volunteer Study

    Enrollment
    28
    Start
    Jan 2024
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT06050291
  • Phase 1
    Completed

    A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

    Obicetrapib, Atorvastatin Calcium

    Healthy Volunteers

    Enrollment
    74
    Start
    Nov 2023
    Primary Completion
    Dec 2023
    Completion
    Jan 2024
    NCT06081166
  • Phase 1
    Completed

    Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

    Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)

    Healthy Volunteers

    Enrollment
    30
    Start
    Feb 2024
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT06250205
  • Phase 1
    Completed

    A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

    Obicetrapib 10mg, Ezetimibe 10mg

    Healthy Volunteers

    Enrollment
    94
    Start
    Oct 2024
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT06547359
Search ClinicalTrials.gov for “NewAmsterdam Pharma”